[go: up one dir, main page]

CA2323067A1 - Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite - Google Patents

Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite Download PDF

Info

Publication number
CA2323067A1
CA2323067A1 CA002323067A CA2323067A CA2323067A1 CA 2323067 A1 CA2323067 A1 CA 2323067A1 CA 002323067 A CA002323067 A CA 002323067A CA 2323067 A CA2323067 A CA 2323067A CA 2323067 A1 CA2323067 A1 CA 2323067A1
Authority
CA
Canada
Prior art keywords
cell
tumor
cells
producer
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323067A
Other languages
English (en)
Inventor
Larry R. Kaiser
Steven M. Albelda
George Coukos
Katherine L. Molnar-Kimber
David J. Caparrelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of CA2323067A1 publication Critical patent/CA2323067A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des cellules productrices qu'il est possible d'administrer à un patient porteur de cellules cancéreuses dans le but de détruire lesdites cellules cancéreuses ou d'éviter la croissance ou la propagation de la tumeur. Une telle cellule productrice comporte un virus oncolytique qui est apte à la réplication dans ladite cellule productrice. La cellule productrice n'est pas capable de survivre de manière prolongée dans le corps du patient. L'invention se rapporte également à des méthodes d'utilisation de telles cellules productrices pour traiter un patient porteur de cellules cancéreuses et à des méthodes de fabrication d'un médicament pouvant être utilisé dans ce type de traitement.
CA002323067A 1998-03-12 1999-03-12 Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite Abandoned CA2323067A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7768198P 1998-03-12 1998-03-12
US60/077,681 1998-03-12
PCT/US1999/005466 WO1999045783A1 (fr) 1998-03-12 1999-03-12 Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite

Publications (1)

Publication Number Publication Date
CA2323067A1 true CA2323067A1 (fr) 1999-09-16

Family

ID=22139477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323067A Abandoned CA2323067A1 (fr) 1998-03-12 1999-03-12 Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite

Country Status (4)

Country Link
EP (1) EP1061806A4 (fr)
AU (1) AU3001799A (fr)
CA (1) CA2323067A1 (fr)
WO (1) WO1999045783A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
WO2000062735A2 (fr) 1999-04-15 2000-10-26 Pro-Virus, Inc. Traitement de neoplasmes avec des virus
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AU782402B2 (en) * 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
AU782020B2 (en) 1999-11-12 2005-06-30 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
CA2398343A1 (fr) * 2000-01-21 2001-07-26 Biovex Limited Souches virales pour le traitement oncolytique du cancer
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
CA2430495A1 (fr) * 2000-12-01 2002-06-06 University Of Ottawa Virus oncolytique
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
EP1515747A4 (fr) * 2002-04-26 2006-05-10 Wellstat Biologics Corp Traitement a base d'agents immunogenes mettant en oeuvre la plasmapherese ou l'exsanguinotransfusion
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20070134202A1 (en) * 2003-10-15 2007-06-14 The New Industry Reserch Organization Cancer gene therapeutic drug
US20070077231A1 (en) 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
US20100086522A1 (en) * 2006-07-18 2010-04-08 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
CN112599225A (zh) 2011-11-17 2021-04-02 拜耳医药保健有限公司 用于确定在医疗过程中使用的方案的方案拟定客户端
JP6358831B2 (ja) * 2014-03-31 2018-07-18 雄行 濱田 新規細胞、それを用いた抗腫瘍効果の誘導剤、癌の遺伝子治療用医薬および抗腫瘍効果の誘導方法
CN104958324A (zh) * 2015-05-29 2015-10-07 黄波 一种溶瘤病毒制剂及其制备方法
US11430558B2 (en) 2017-07-07 2022-08-30 Bayer Healthcare Llc System, method, and computer program product for peer exchange of data between injection systems
US20210054332A1 (en) * 2017-12-29 2021-02-25 Genemedicine Co., Ltd Cell sheet for gene delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659209A1 (fr) * 1991-07-26 1995-06-28 The University Of Rochester Therapie du cancer faisant appel a des cellules malignes
JPH09505561A (ja) * 1993-10-01 1997-06-03 アメリカ合衆国 神経系の遺伝子治療
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
EP0895476B1 (fr) * 1996-01-25 2003-06-04 The University Court Of The University Of Glasgow Mutant 1716 de hsv destine au traitement des mesotheliomes

Also Published As

Publication number Publication date
AU3001799A (en) 1999-09-27
WO1999045783A1 (fr) 1999-09-16
EP1061806A1 (fr) 2000-12-27
EP1061806A4 (fr) 2001-09-12

Similar Documents

Publication Publication Date Title
CA2323067A1 (fr) Cellules productrices pour virus aptes a la replication utilisees dans le traitement de la malignite
Fountzilas et al. Oncolytic virotherapy, updates and future directions
Coukos et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer
Wakimoto et al. Human glioblastoma–derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
Watanabe et al. Oncolytic virotherapy by HSV
Campadelli‐Fiume et al. Rethinking herpes simplex virus: the way to oncolytic agents
Ning et al. Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy
Blank et al. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation
Adusumilli et al. Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses
Coukos et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
Cinatl Jr et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma
Jefferson et al. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer
Malhotra et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas
US20080014175A1 (en) Methods and Compositions for Viral Enhancement of Cell Killing
Todo et al. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replicationcompetent herpes simplex virus tumor therapy
Xu et al. Oncolytic vaccinia virus and cancer immunotherapy
Li et al. Oncolytic virotherapy for ovarian cancer
EP1173598A1 (fr) Facteur derive de l'herpes simplex virus de type 1(hsv-1) utile pour inhiber de maniere selective des cellules malignes et procedes d'utilisation de ce dernier pour traiter des cancers et pour exprimer des caracteristiques desirees dans des cellules malignes et non malignes de mammiferes
Hu et al. Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
Sadri et al. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
CA2326323A1 (fr) Combinaison d'adenovirus et de chimiotherapie pour le traitement du cancer
Jiang et al. Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro
WO2003073918A2 (fr) Prevention de recurrence et de metastase cancereuses
Yang et al. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells
US8216564B2 (en) Composite oncolytic herpes virus vectors

Legal Events

Date Code Title Description
FZDE Dead